Rifaximin Versus Placebo in the Prevention of Travelers' Diarrhea - Tabular View

Home

Study Topics

Glossary


	Full Text View


	Tabular View


	Contacts and Locations


	Related Studies

Rifaximin Versus Placebo in the Prevention of Travelers' Diarrhea

This study has been completed.
Information provided by DuPont, Hurbert L., MD

This Tabular View shows the required WHO registration data elements as marked by ^†

Descriptive Information Fields
Brief Title ^†	Rifaximin Versus Placebo in the Prevention of Travelers' Diarrhea
Official Title ^†	A Randomized, Double-Blind, Single Center, Comparative Dose Ranging Study of Rifaximin Vs. Placebo in the Prevention of Travelers' Diarrhea Due to Enteropathogenic Bacteria
Brief Summary	The purpose of this study is to evaluate the effectiveness of poorly absorbed rifaximin in the prevention of travelers' diarrhea among U.S. college students in Mexico for five weeks.
Detailed Description	This is an investigator-initiated proposal wherein 220 male and female subjects >17 years of age from industrialized regions were randomized to receive a poorly absorbed antibiotic, rifaximin, in one of three doses at mealtime (when they are exposed to diarrhea-causing bacteria), 200 mg once a day, 200 mg twice a day or 200 mg three times a day versus a placebo starting on arrival (within the first 72 hours) to Mexico and continuing for two weeks with diaries of symptoms recorded for three weeks. Adverse events in the subjects were followed for five weeks. If mild diarrhea (1 or 2 unformed stools/24 hours plus an enteric symptom) or diarrheal illness (>2 unformed stools/24 hours plus an enteric symptom) developed, subjects provided a stool sample to determine cause of illness. Forty subjects provided stool samples after 7 days and 14 days treatment to see if their intestinal bacterial flora had developed resistance to rifaximin and to see the level of drug achieved. Stool samples from these forty subjects were studied for enteric pathogens to look for asymptomatic infection during the period of prophylaxis. The stool samples collected were initially processed in our enteric laboratories in Guadalajara, Mexico. Specialized tests such as studies of toxigenicity for enterotoxigenic E. coli and enteroadherence for enteroaggregative E. coli were done in Houston.
Study Phase	Phase II
Study Type ^†	Interventional
Study Design ^†	Prevention, Randomized, Double-Blind, Placebo Control, Parallel Assignment, Efficacy Study
Primary Outcome Measure ^†	Occurrence of diarrhea, defined as passage of >2 unformed stools/24 hr plus one or more signs or symptoms of enteric infection
Secondary Outcome Measure ^†	Occurrence of mild diarrhea (1 or 2 unformed stools/24 hr plus a sign or symptom) Treatment failure (not well in five days) Occurrence of moderate to severe abdominal pain/cramps or intestinal gas related symptoms
Condition ^†	Diarrhea
Intervention ^†	Drug: rifaximin
MEDLINE PMIDs	15897530, 11692292, 8502272
Links

Recruitment Information Fields
Recruitment Status ^†	Completed
Enrollment ^†	220
Start Date ^†	June 2003
Completion Date	September 2003
Eligibility Criteria ^†	Inclusion Criteria: An Investigational Review Board approved, written informed consent is appropriately witnessed, signed and dated prior to any study-related activities Male or female subjects 18 years of age or older Able to read and understand English Enrolled and started on prophylaxis within 72 hours of arrival in Mexico If the subject is female, only women with non-childbearing potential or those who are not pregnant will be eligible. Urine pregnancy tests will be performed on those women who question their pregnancy status. Women on the study are required to employ a reliable method of contraception while taking medication. Forms of acceptable contraception include: Double barrier method of contraception. Oral birth control pills for at least two cycles before enrollment and continuing during therapy – subjects will be told they should use a barrier contraception method during the study as well. Norplant inserted at least one month before enrollment. An intrauterine device inserted by a qualified clinician. Medroxyprogesterone acetate for a minimum of one month before study and administered for one month following study completion. An approved birth control patch for at least two cycles before enrollment and continuing during therapy. OR Complete abstinence from intercourse for the two weeks of medication. Exclusion Criteria: Acute diarrhea (criteria for travelers’ diarrhea above) within the past week Diarrhea developing within 24 hours of study enrollment In Mexico for more than 72 hours Receipt of one of the following classes of drugs: fluoroquinolone (any drug in class), macrolide or azalide or trimethoprim-sulfamethoxazole within the past week or during the three week study Receipt of other medication to decrease the occurrence of diarrhea (e.g. bismuth subsalicylate or lactobacillus preparations) For females, pregnancy or breast feeding during the three week study Receipt of antidiarrheal medication (loperamide, bismuth subsalicylate, kaopectate) within 24 hours of enrollment Hypersensitivity to rifaximin Unstable medical condition including chronic renal failure and insulin dependent diabetes.
Gender	Both
Ages	18 Years and older
Accepts Healthy Volunteers	Yes
Contacts ^††
Location Countries ^†	Mexico

Administrative Information Fields
NCT ID ^†	NCT00098384
Organization ID	PR 03
Secondary IDs ^††
Study Sponsor ^†	DuPont, Hurbert L., MD
Collaborators ^††	Salix Pharmaceuticals The University of Texas Health Science Center, Houston
Investigators ^†
Information Provided By	DuPont, Hurbert L., MD
Verification Date	December 2004
First Received Date ^†	December 7, 2004
Last Updated Date	May 8, 2006

^† Required WHO trial registration data element.
^†† WHO trial registration data element that is required only if it exists.